Auswahl der wissenschaftlichen Literatur zum Thema „Cer-001“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Cer-001" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Cer-001"
Zheng, Kang He, Fleur M. van der Valk, Loek P. Smits, Mara Sandberg, Jean-Louis Dasseux, Rudi Baron, Ronald Barbaras et al. „HDL mimetic CER-001 targets atherosclerotic plaques in patients“. Atherosclerosis 251 (August 2016): 381–88. http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.038.
Der volle Inhalt der QuelleOssoli, A., A. Strazzella, S. Simonelli, D. Rottoli, M. Abbate, C. M. Zoja, J. L. Dasseux und L. Calabresi. „Remodeling And Catabolism Of Cer-001 In Absence Of Lcat Enzyme“. Atherosclerosis 287 (August 2019): e107. http://dx.doi.org/10.1016/j.atherosclerosis.2019.06.312.
Der volle Inhalt der QuelleKeyserling, Constance H., Ronald Barbaras, Renee Benghozi und Jean-Louis Dasseux. „Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings“. Clinical Drug Investigation 37, Nr. 5 (17.02.2017): 483–91. http://dx.doi.org/10.1007/s40261-017-0506-3.
Der volle Inhalt der QuelleNicholls, Stephen J., Jordan Andrews, John J. P. Kastelein, Bela Merkely, Steven E. Nissen, Kausik K. Ray, Gregory G. Schwartz et al. „Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial“. JAMA Cardiology 3, Nr. 9 (01.09.2018): 815. http://dx.doi.org/10.1001/jamacardio.2018.2121.
Der volle Inhalt der QuelleLi, Chen, Pan Pan Wu und Kun Zhang. „Preparaitve Separation and Purification of Cordycepin from Cultured Cordyceps militaris Using Cation Exchange Resin“. Advanced Materials Research 550-553 (Juli 2012): 1773–78. http://dx.doi.org/10.4028/www.scientific.net/amr.550-553.1773.
Der volle Inhalt der QuelleFlores-Peña, Yolanda, María Eugenia Pérez-Campa, Hermelinda Ávila-Alpirez, Juana Mercedes Gutiérrez-Valverde und Gustavo Gutiérrez-Sánchez. „Depressive symptoms, maternal feeding styles, and preschool child’s body weight“. Salud mental 44, Nr. 6 (02.12.2021): 261–66. http://dx.doi.org/10.17711/sm.0185-3325.2021.034.
Der volle Inhalt der QuelleFaguer, Stanislas, Magali Colombat, Dominique Chauveau, Pauline Bernadet-Monrozies, Audrey Beq, Audrey Delas, Vincent Soler et al. „Administration of the High-Density Lipoprotein Mimetic CER-001 for Inherited Lecithin–Cholesterol Acyltransferase Deficiency“. Annals of Internal Medicine 174, Nr. 7 (Juli 2021): 1022–25. http://dx.doi.org/10.7326/l20-1300.
Der volle Inhalt der QuelleNicholls, Stephen J., Jordan Andrews, John Jp Kastelein, Bela Merkely, Steven E. Nissen, Kausik Ray, Gregory G. Schwartz et al. „CARAT: will infusing a pre-beta high-density lipoprotein mimetic (CER-001) regress coronary atherosclerosis?“ Atherosclerosis 263 (August 2017): e10. http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.060.
Der volle Inhalt der QuelleOssoli, A., A. Strazzella, D. Rottoli, C. Zanchi, M. Locatelli, C. Zoja, S. Simonelli et al. „CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency“. Atherosclerosis 331 (August 2021): e39. http://dx.doi.org/10.1016/j.atherosclerosis.2021.06.112.
Der volle Inhalt der QuelleFaguer, S., M. Colombat, D. Chauveau, P. Bernadet, A. Delas, V. Soler, I. Labadens, A. Huart und J. Schanstra. „Place du mimétique HDL CER-001 dans la glomérulopathie secondaire aux déficits en lécithine-cholestérol acyltransférase (LCAT)“. Néphrologie & Thérapeutique 17, Nr. 5 (September 2021): 317–18. http://dx.doi.org/10.1016/j.nephro.2021.07.182.
Der volle Inhalt der QuelleDissertationen zum Thema "Cer-001"
Begue, Floran. „Lipoprotéines de haute densité (HDL). Implications diagnostiques et thérapeutiques au cours de la COVID 19“. Electronic Thesis or Diss., La Réunion, 2024. http://www.theses.fr/2024LARE0002.
Der volle Inhalt der QuelleHigh-density lipoproteins (HDL) are crucial for maintaining good cardiovascular health due to their ability to transport cholesterol from peripheral tissues to the liver for elimination via a "reverse transport of cholesterol” mechanism. Moreover, HDL exhibits several other advantageous properties, including anti-inflammatory, antioxidant, and anti-infectious activities. In inflammatory situations, such as those encountered during viral infections, HDL can undergo both quantitative alterations, with a drop in circulating concentration, and qualitative alterations, such as a change in composition and loss of protective activities. Humanity is still struggling with coronavirus disease (COVID-19), characterized by acute inflammation and responsible for over 6.9 million deaths worldwide to date. The aim of my thesis was to characterize the quantitative and qualitative changes in HDL during COVID-19, to identify specific biomarkers of the changes found in HDL, and to conduct a therapeutic trial of HDL mimetic supplementation during this disease. Quantification of circulating lipoproteins in the plasma of patients with severe COVID 19 shows a significant decrease in HDL and other lipoproteins, which may be predictive biomarkers of disease severity. Analysis of lipoprotein distribution shows a pro-atherogenic profile, with the presence of small, dense low-density lipoproteins (LDL) in the plasmas of patients with severe COVID-19. Qualitative mass spectrometry analysis of the composition of both HDL and LDL showed an increased presence of proteins from the acute phase of inflammation, to the detriment of the apoprotein part of these lipoproteins when isolated from the plasma of COVID-19 patients. When tested on human endothelial cells from primary culture, HDL demonstrated a significant alteration in their anti-apoptotic and anti-inflammatory properties when purified from the plasma of COVID-19 patients. Finally, the anti-inflammatory properties of recombinant HDL injections were demonstrated in a patient admitted to intensive care with a severe form of COVID-19. In conclusion, my thesis work provides some new insights into lipoprotein modifications during infectious disease, in this case COVID-19. It also opens up promising prospects for research into the use of HDL both as a biomarker of inflammatory disease severity and as a means of therapeutic control